Pardes Biosciences Inc
Pardes Biosciences Inc Stock, NASDAQ:PRDS
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. It develops oral antiviral drugs to treat and prevent various infections caused by coronavirus. The firm's product candidate, PBI-0451, is being developed as a potential direct-acting and oral antiviral drug to treat and prevent SARS-CoV-2 infections and associated diseases. The company was founded by Uri A. Lopatin and Lee D. Arnold on February 27, 2020 and is headquartered in Carlsbad, CA.